NCT05203445View on ClinicalTrials.gov

A Study of Olaparib and Pembrolizumab in People with Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

January 31, 2022

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Breast Cancer
Interventions
DRUG

Olaparib

Olaparib 300 mg orally BID

DRUG

Pembrolizumab

Pembrolizumab 400 mg intravenously q6weeks

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

Memorial Sloan Kettering Westchester (Limited Protocol Activities), East White Plains

11553

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11725

Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities), Commack

07920

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER